These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20494607)

  • 21. Botulinum toxin in the treatment of dystonias--a hospital based study.
    Gupta M; Singh G; Khwaja G
    J Assoc Physicians India; 2003 May; 51():447-53. PubMed ID: 12974424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A.
    Brashear A; Ambrosius WT; Eckert GJ; Siemers ER
    Mov Disord; 1998 Jan; 13(1):158-61. PubMed ID: 9452343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
    Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B
    J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pyridostigmine for reversal of severe sequelae from botulinum toxin injection.
    Young DL; Halstead LA
    J Voice; 2014 Nov; 28(6):830-4. PubMed ID: 25008379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy of Botulinum toxin in classical achalasia: a prospective study.
    Kolbasnik J; Waterfall WE; Fachnie B; Chen Y; Tougas G
    Am J Gastroenterol; 1999 Dec; 94(12):3434-9. PubMed ID: 10606299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term botulinum toxin efficacy, safety, and immunogenicity.
    Mejia NI; Vuong KD; Jankovic J
    Mov Disord; 2005 May; 20(5):592-7. PubMed ID: 15645481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained attention in cranial dystonia patients treated with botulinum toxin.
    Allam N; Frank JE; Pereira C; Tomaz C
    Acta Neurol Scand; 2007 Sep; 116(3):196-200. PubMed ID: 17714334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Convergence spasm treated with botulinum toxin.
    Kaczmarek BB; Dawson E; Lee JP
    Strabismus; 2009; 17(1):49-51. PubMed ID: 19301195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of botulinum toxin therapy in otorhinolaryngology: experience from 1,000 treatments.
    Helmstaedter V; Wittekindt C; Huttenbrink KB; Guntinas-Lichius O
    Laryngoscope; 2008 May; 118(5):790-6. PubMed ID: 18300708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cervical dystonia: a review the role of botulinum toxin.
    Edwards LL; Normand MM; Wszolek ZK
    Nebr Med J; 1995 May; 80(5):109-15. PubMed ID: 7791942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Botulinum toxin for people with dystonia treated by an outreach nurse practitioner: a comparative study between a home and a clinic treatment service.
    Whitaker J; Butler A; Semlyen JK; Barnes MP
    Arch Phys Med Rehabil; 2001 Apr; 82(4):480-4. PubMed ID: 11295008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
    Grosse J; Kramer G; Jakse G
    BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oromandibular dystonia: long-term management with botulinum toxin.
    Sinclair CF; Gurey LE; Blitzer A
    Laryngoscope; 2013 Dec; 123(12):3078-83. PubMed ID: 24122897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interventional neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A.
    Heinen F; Wissel J; Philipsen A; Mall V; Leititis JU; Schenkel A; Stücker R; Korinthenberg R
    Neuropediatrics; 1997 Dec; 28(6):307-13. PubMed ID: 9453027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore.
    Tan AK
    Singapore Med J; 1998 Sep; 39(9):403-5. PubMed ID: 9885719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuralgic amyotrophy following botulinum toxin injection.
    Alcalay RN; Simões RM; Feigin A; Frucht S
    Parkinsonism Relat Disord; 2010 May; 16(4):301-2. PubMed ID: 19815448
    [No Abstract]   [Full Text] [Related]  

  • 38. Management of dystonia of the lateral pterygoid muscle with botulinum toxin A.
    Mendes RA; Upton LG
    Br J Oral Maxillofac Surg; 2009 Sep; 47(6):481-3. PubMed ID: 18829144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.
    Brin MF; Fahn S; Moskowitz C; Friedman A; Shale HM; Greene PE; Blitzer A; List T; Lange D; Lovelace RE
    Mov Disord; 1987; 2(4):237-54. PubMed ID: 3504553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.
    Karsenty G; Elzayat E; Delapparent T; St-Denis B; Lemieux MC; Corcos J
    J Urol; 2007 Mar; 177(3):1011-4. PubMed ID: 17296399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.